“

The FDA will closely monitor the effects of moving to a 12-month deferral for MSM over the next few years in order to help ensure that blood safety is maintained. At the same time, the FDA will continue to review its donor deferral policies to ensure they reflect the most up-to-date scientific knowledge. This process must be data-driven, so the timeframe for future changes is not something we can predict.